How significant is the 4,170-share CTNM sale relative to the insider’s position?

The transaction involves 4,170 shares sold, while post-transaction direct holdings remain at 147,712 shares. This indicates the sale represents only a small fraction of his reported direct ownership, with additional indirect holdings of 6,842 shares through his spouse also disclosed.

Pre-planned stock sale by Contineum (CTNM) chief scientific officer

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock. The shares were sold at a weighted average price of $13.4326 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.

After the sale, he directly holds 147,712 shares. In addition, 6,842 shares are held indirectly by his spouse. The sale price reflected multiple trades within a range of $13.08 to $13.60 per share.

Insider Trade Summary 10b5-1

Net Seller: 4,170 shares ($56,014)

Net Sell 2 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 4,170 shs ($56K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	4,170	$13.4326	$56K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 147,712 shares (Direct); Class A Common Stock — 6,842 shares (Indirect, By Spouse)

Footnotes (1)

These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Key Figures

Shares sold: 4,170 shares Weighted average sale price: $13.4326 per share Post-sale direct holdings: 147,712 shares +2 more

5 metrics

Shares sold 4,170 shares Open-market sale on April 6, 2026

Weighted average sale price $13.4326 per share Class A Common Stock sale

Post-sale direct holdings 147,712 shares Direct ownership after transaction

Indirect holdings by spouse 6,842 shares Held indirectly through spouse

Trade price range $13.08–$13.60 per share Prices for individual sale executions

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, indirect ownership

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"total_shares_following_transaction: 6842.0000, direct_or_indirect: I, nature_of_ownership: By Spouse"

Form 4 Insider Transactions: What Each Field Means →

04/06/2026 - 05:43 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last)

(First)

(Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	04/06/2026		S⁽¹⁾		4,170	D	$13.4326⁽²⁾	147,712	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Contineum Therapeutics (CTNM) disclose in this Form 4?

Contineum Therapeutics disclosed that Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A Common Stock. The transaction was an open-market sale at a weighted average price of $13.4326 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices did the CTNM insider shares trade in this sale?

The reported sale used a weighted average price of $13.4326 per share. According to the filing, individual trades occurred in a price range from $13.08 to $13.60, and detailed trade breakdowns are available on request from the issuer, security holders, or SEC staff.

How many CTNM shares does the chief scientific officer hold after this transaction?

Following the reported sale, Daniel S. Lorrain directly owns 147,712 shares of Contineum Therapeutics Class A Common Stock. The filing also notes an additional 6,842 shares held indirectly through his spouse, giving investors visibility into both direct and indirect holdings.

Was the CTNM insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Daniel S. Lorrain on September 23, 2025. Such pre-arranged plans schedule trades in advance, which can make the timing less indicative of short-term market views.

Does this CTNM Form 4 show any option exercises or derivative transactions?

No derivative transactions are reported in this filing. The derivative section is empty, and the only reported trade is an open-market sale of 4,170 shares of Class A Common Stock, simplifying the picture of the chief scientific officer’s equity activity in this instance.